USNA auf dem Weg zu 500% dieses Jahr.

Allmählich geht mir das Kursziel aus.

Bis morgen, dann geh ich Euch wieder auf den Wecker.

Gruss E.

Ich hatte Sie Dir zu 0,70 das letzte Mal ans Herz gelegt im November. Und falls grenke
mitliest, der weiss auch das Prof. Dr Jürgen Drews nicht nur Vorstand von GPC Biotech, Morphosys, Protein Design, Humane Genome ist, sondern auch Aufsichtsratsvorsitzender von Genaissance Pharmaceuticals in New Haven. Nur die kennt halt niemand hier zu Lande.

Gruss E.

Schaue jetzt heute-journal, tschüss für heute.

chart.bigcharts.com/bc3/quickchart/...45&mocktick=1&rand=5536"


 24.01.2003   1,41   1,44   1,25   1,40   110.800  
 23.01.2003   1,33   1,37   1,31   1,31   42.000  
 22.01.2003   1,30   1,39   1,30   1,34   33.000  
 21.01.2003   1,26   1,47   1,25   1,40   173.000  
 20.01.2003   1,25   1,25   1,20   1,21   32.900  
 17.01.2003   1,21   1,21   1,20   1,21   32.900  
 16.01.2003   1,25   1,29   1,21   1,25   63.233  
 15.01.2003   1,22   1,25   1,20   1,20   7.900  
 14.01.2003   1,25   1,26   1,20   1,20   12.897  
 13.01.2003   1,20   1,25   1,18   1,25   26.803  
 10.01.2003   1,14   1,25   1,00   1,19   38.036  
 09.01.2003   1,06   1,18   1,06   1,18   49.600  
 08.01.2003   1,05   1,11   1,05   1,09   154.100  
 07.01.2003   1,08   1,27   0,87   1,04   260.229  
 06.01.2003   0,80   0,92   0,80   0,87   17.650  
 03.01.2003   0,90   0,90   0,81   0,87   23.800  
 02.01.2003   0,88   0,93   0,86   0,88   22.100  
 01.01.2003   0,84   0,94   0,83   0,87   101.784  
 31.12.2002   0,84   0,94   0,83   0,87   101.784  

Klar erinner ich mich...
Bin gerade intensiv an der Aufarbeitung der vergangenen Woche, wo ich im Skiurlaub war. Ist einiges zu tun...
Aber durch USA/Irak gibt es in diesen Tagen einiges zu Schleuderpreisen (passt ja zum Start des WSV..)

Bis morgen
Pavian

Und Pavian bin mal gespannt ob BPRX oder USNA höher steigen. Was für geniale Perlen.

Gruss E.

Ja, ja kauft nur Poet und den ganzen Rotz. Im Oktober war mein Kursziel 12 Dollar, als Usana die 8 Dollar genommen hatte.
Und jetzt?...... Will ich fünf grüne Punkte, sonst verrat ich Euch nix mehr.

Gruss E.

Umsatz + 43% auf USD 28.6 Mio.
Gewinn +220% auf USD 3.6 Mio. oder 34 Cents
EPS für 2003 auf USD 1.40 angehoben ---> KGV 17!

Und die gab es vor einem Jahr noch für 1 Dollar... tz tz tz...

chart.bigcharts.com/bc3/quickchart/...lf2=0&lf3=0&type=2&size" style="max-width:560px" >

52-weeks low bei 0,18, akt bei 3,63

EVOLVING SYSTEMS INC - Nasdaq SmallCap Market: EVOL
Consolidated Real-time Market Quote*

Last	Change (%)	After Hours Chg (%)**	Bid	Ask	Trade Time
--	--	quotes.freerealtime.com/gra/uparrow1.gif" style="max-width:560px" > 0.279 (7.69)	0 (0)	0 (0)	--

---

Exchange Quote

Last	Change (%)	Bid (size)	Ask (size)	Trade Time
3.63	quotes.freerealtime.com/gra/uparrow1.gif" style="max-width:560px" > 0.23 (6.76)	0.01 (1)	4.76 (20)	15:59
Day Volume	Last Size	Open	High	Low
0	100	3.55	3.72	3.40
Latest Ticks	# of Trades	Avg Trade Size	52 Wk High	52 Wk Low
--==	271	0	3.65	0.18
Prev Close	Avg Day Vol
3.40	182,900

chart.bigcharts.com/bc3/quickchart/...ocktick=1&rand=4726" style="max-width:560px" border=0>

Usana hat die 40 Dollar geknackt.

Gruss E.

Wer kennt eine bessere Aktie nach 70 Wochen. Niemand, garantiert.

chart.bigcharts.com/bc3/quickchart/...91&mocktick=1&rand=1166"

Gruss E.

Usana wird heute die 50 Dollar wieder überspringen. Gestern nach Börsenschluss wiederum perfekte Zahlen, Forecasts für 2003 wurden auf 1.65 angehoben. Das sieht stark aus!

Grüße Pavian

Biotechs, aber von USNA habe ich hier zugegebenermaßen das erste mal gehört. Ich bin beeindruckt!

Wie bist Du aus USNA aufmerksam geworden? Woher beziehst Du Deine Infos?

Gruß
Kalle

Wenn ich noch richtig informiert bin, ließt Eskimato wie ich auch den Börsenbrief Global Biotech Investing (Infos und Probeabo unter www.boerse-inside.de). Die haben USana letztes Jahr das erste Mal bei 6 Dollar empfohlen und sind auch so ganz nützlich. Musterdepot liegt zur Zeit so ca. 50% vorne seit Januar.

Überwiegend arbeiten wir (schau mal in den US-Depotwettbewerb hier im Board) viel mit dem Internet. Da steckt richtig Arbeit dahinter, News suchen, Zahlen bewerten, Charts analysieren...

Hoffe ich konnte Dir ein wenig weiterhelfen.

Beste Grüße
Pavian

f.h. hatte zu 3,63 empfohlen...

Gruss E.

4:33PM USANA, Inc guides Q3 above previous forecast (USNA) 52.15 +5.35: Company guides Q3, sees EPS of $0.54, including $0.03 for an adjustment of co's effective tax rate for '03,  vs previous guidance of $0.43-0.45, and sees revenues of $52 mln, in line with prior guidance.

Legen nachbörslich über 2$ zu.

Schon unglaublich das TEil!
Habe ich hier oft genug angesprochen.

Grüße
an alle
Pavian

Bestimmt.

Gruss E.

gfx.finanztreff.de/charts/...SC&boerse=16&zeit=10000&land=840"

Bis zum Wochenende, zur Tradingrunde.

Gruss E.

GENAISSANCE PHARMA INC

function setFocus(){     if(document.symbol_entry.p) {          document.symbol_entry.p.focus() ;          document.symbol_entry.p.select() ;     }}var myWin = nullfunction openTSL(url){     if(!myWin || myWin.closed)     {          myWin=window.open(url, "TslWin", "width=600,height=515,status=no,toolbar=no,menubar=no,scrollbars=yes,resizable=yes");     }     else     {          myWin.focus("TslWin");     }}function go(tab,params){     if(document.symbol_entry.p)     {          var tmp=document.symbol_entry.p.value          var symlist=''          if (params == null)               params = ""          var x=0;          while(tmp.charAt(x)==' ') tmp=tmp.substring(1);          x=tmp.length-1;          while(tmp.charAt(x)==' ') tmp=tmp.substring(0,x--);          x=tmp.length-1;          while(tmp.charAt(x)==',') tmp=tmp.substring(0,x--);          while((x=tmp.indexOf('+'))>0)          {               symlist+=tmp.substring(0,x)               symlist+='%2B'               tmp=tmp.substring(x+1)          }          p=(location.href).indexOf("p=")          while((x=tmp.indexOf(' '))>0)          {               symlist+=tmp.substring(0,x)               if(p>-1)                 symlist+='+'               else                 symlist+=','               while(tmp.charAt(x) == ' ') x++               tmp=tmp.substring(x)          }          symlist+=tmp;          if (tab.indexOf("quickenbrokerage") > -1)            location.href=tab+'?'+'symbol='+symlist+params          else            location.href=tab+'?'+'p='+symlist+params     }}function SpaceToDot(tickers){          var tmp=document.symbol_entry.p.value          var symlist=''          while((x=tmp.indexOf(' '))>0)          {               symlist+=tmp.substring(0,x)               symlist+='.'               tmp=tmp.substring(x+1)          }          symlist+=tmp;          return symlist;}            

You can't navigate in the Quotes & Research area without a Javascript-enabled browser.
	Enter symbol(s):   Don't know the symbol? - 0){tmp+=sym.substring(0,x)+s; sym=sym.substring(x+1)}; return tmp+sym}; var tickers=document.symbol_entry.p.value; tickers=subst(tickers,'+','%2B'); tickers=subst(tickers,' ','%20'); tickers=subst(tickers,',','%2C'); location.href='/investments/portfolio/AddToPort/?AddToPortfolio=1&p='+tickers+'&ref=quotes&channel=investments'}">Add to your watchlist - Printer-friendly version			if(typeof ad3 != "undefined") {document.write(ad3)};

Full Quote

Quick Quote

Day's Overview

Last 5 Days

Real-Time Quote

Options

GNSC

Last Trade	2.48	Volume	248,725
Change	+0.38 (+18.10%)	Avg Volume	121,496
Bid / Ask	2.32 / 2.40	Mkt Cap (mil)	$57.14
Open	2.11	P/E	N/E*
Prev Close	2.10	Div Yield	N/A
Day's Range	2.07 - 2.50	Annual Div/Sh	None
52-wk Range	0.37 - 2.26	Market	NASDAQ
function getQstrVal(name) { var RE = new RegExp('(?|&)' + name + '=([^s]+)(&|)'); if (location.search) return unescape(RE.exec(location.search)[2]); } var tickerSym = getQstrVal('p'); document.write(""); Free Zacks Stock Analysis for GNSC

*N/E - No Earnings

Thursday, October 02, 2003 03:58 PM EDT.  Quote delayed: 15 minutes Nasdaq, 20 minutes others.

Recent Headlines

Wed Oct 01, 2003
•	Genaissance Appoints Karen A. Dawes to Board of Directors PR Newswire - 07:30 AM EDT
Thu Sep 25, 2003
•	RX Communications Group is Awarded an Honorable Mention for Financial/Investor Relations From PR News PR Newswire - 03:46 PM EDT
Wed Sep 17, 2003
•	Genaissance Reaches Milestone in CARING Study PR Newswire - 07:30 AM EDT
Thu Sep 11, 2003
•	Genaissance shares lifted by AstraZeneca deal Hosted by CBS MarketWatch - 08:36 AM EDT
•	Genaissance Pharmaceuticals and AstraZeneca Sign Pharmacogenomics Based Agreement PR Newswire - 07:30 AM EDT
Wed Aug 13, 2003
•	Genaissance Pharmaceuticals Reports Second Quarter Results PR Newswire - 07:30 AM EDT
Wed Jul 30, 2003
•	Genaissance Pharmaceuticals, Inc. Invites You to Participate in its Second Quarter 2003 Conference Call PR Newswire - 07:31 AM EDT
Tue Jul 29, 2003
•	Genaissance Pharmaceuticals Announces Scientific Management Changes PR Newswire - 10:51 AM EDT
Tue Jul 08, 2003
•	Genaissance Pharmaceuticals Appoints Skip Klein to Board of Directors PR Newswire - 07:30 AM EDT

Neues All-Time-High gestern!

Grüße
Pavian

...gestern ein neues All-Time-High bei 59.01 Dollar!

Einfach der Wahnsinn!

Grüße
Pavian

23:28 14Oct2003 RTRS-UPDATE 1-USANA Health profit grows, sets stock split

(Adds details, outlook, stock activity)
   PALO ALTO, Calif., Oct 14 (Reuters) - USANA Health Sciences Inc.  on Tuesday posted higher third-quarter earnings,  raised its forecast for the fourth quarter and announced a stock split.
   The company Salt Lake City-based maker of nutritional, personal care and weight management products, said its board approved a 2-for-1 stock split.
   USANA shares, which had closed at $54.74 on the Nasdaq, were up 4 percent to $57 in extended trade on Instinet.
   For its fiscal third quarter ended Sept. 27, USANA said net earnings rose to $6.1 million, or 57 cents per diluted share, from $2.3 million, or 22 cents per diluted share in the year ago period. Net sales grew to $52.5 million from $34.8 million a year ago.
   The company attributed the increase in earnings to positive exchange rates and the opening of the South Korean market.
   USANA said it bumped up guidance based on the third-quarter's results, forecasting fourth-quarter net sales approaching $57 million and earnings in the range of 57 cents to 59 cents a share, on a pre-split basis.
   For 2004, USANA forecast sales of $240 million to $250 million and earnings of $2.45 per share to $2.55 per share, on a pre-split basis.
   The company said the stock split will be effected by means of a stock dividend and will double the number of outstanding shares to about 19,050,000. Dividend shares will be distributed on or about Oct. 30, to stockholders of record as of Oct. 24, 2003.
((Reporting by Lisa Baertlein; Reuters Messaging: lisa.baertlein.reuters.com@reuters.net; 650-461-3401; Editing by Carol Bishopric))
For Related News, Double Click on one of these codes:
[E] [U] [RNP] [DNP] [PCO] [CRD] [PCU] [DRU] [US] [ISU] [RES] [RESF] [LEN] [RTRS] [USNA.O]

For Relevant Price Information, Double Click on one of these codes:

Tuesday, 14 October 2003 23:28:24
RTRS [nN14183872] {EN}
ENDS

... wieder neues All-Time-High bei 59.84 Dollar!

Grüße
Pavian

Usana meldet praktisch täglich ein neues All-Time-High! Gestern Plus 6% auf 62.80!!

Grüße
Pavian

Gestern weitere 3% auf 65 Dollar!

Wenn ich eine Wert anpreise, dann geht was...., meistens.

Gruss E.

host.wallstreetcity.com/frti/...353-0-1-0-260-400-211-_-0.gif"

Genaissance Pharmaceuticals Secures $11.1 Million in Funding - Financing Package Could Total $15.4 Million -  


NEW HAVEN, Conn., Oct 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Genaissance
Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that it has secured $11.1
million from two transactions with a potential for an additional investment of
$4.3 million.

RAM Trading, Ltd. ("RAM"), an affiliate of an existing investor, purchased
270,000 shares of newly-designated Series A Preferred Stock at a price of $22.50
per share, totaling approximately $6.1 million. The proceeds from the
transaction will be used for working capital and general corporate purposes.
These shares can be converted by RAM at any time into 2.7 million shares of
common stock. The preferred stock pays an annual cash dividend of 2%.
Genaissance also issued a warrant to RAM exercisable for an additional 190,000
shares of Series A Preferred Stock under the same terms until December 31, 2005.
If Genaissance's common stock price is above $4.00 for 23 consecutive business
days, RAM would be required to purchase the additional shares at a specified
time. If Genaissance sells the additional 190,000 shares, RAM's investment would
total approximately $10.4 million. In addition, Genaissance granted RAM certain
other rights, including registration rights and certain put rights that can be
exercised beginning on the third anniversary of the closing of the transaction.

Genaissance also announced that on September 30, 2003, it signed a three-year,
$5.0 million term loan with Comerica Bank. The funds from this loan were
primarily used to help repay all existing capital leases, substantially reducing
Genaissance's annual principal and interest payments.

"This funding completes the restructuring plan for our balance sheet, which we
began last year, and further helps position us financially to execute our
business plan of building the preeminent Pharmacogenetics company," said Kevin
Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals. "We
are extremely pleased by the additional support from an affiliate of one of our
significant shareholders, which we believe is a tangible expression of
confidence in our business."

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of a new generation of DNA-based
diagnostic and therapeutic products. Genaissance markets its technology,
clinical development skills and pharmacogenetic services to the pharmaceutical
industry as a complete solution for improving the development, marketing and
prescribing of drugs. Genaissance has agreements with major pharmaceutical,
diagnostic and biotechnology companies. Genaissance is headquartered in Science
Park in New Haven, Connecticut. Visit the company's website at
www.genaissance.com.

This press release contains forward-looking statements, including statements
about the receipt of additional proceeds from the sale of Series A Preferred
Stock and our expected financial position. Such statements are subject to
certain factors, risks and uncertainties that may cause actual results, events
and performance to differ materially from those referred to in such statements,
including, but not limited to, the trading price of our common stock, our
expected cash proceeds, the attraction of new business and strategic partners,
the adoption of our technologies by the pharmaceutical industry, the timing and
success of clinical trials, competition from pharmaceutical, biotechnology and
diagnostics companies, the strength of our intellectual property rights, and
those risks identified in our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 14, 2003, and in other filings we
make with the Securities and Exchange Commission from time to time. The
forward-looking statements contained herein represent the judgment of
Genaissance as of the date of this release. Genaissance disclaims any obligation
to update any forward-looking statement.

SOURCE Genaissance Pharmaceuticals, Inc.